AbbVie and RemeGen are collaborating on RC148, a novel PD-1/VEGF-targeted bispecific antibody already being developed as a ...
AbbVie is paying $650 million for a dual-targeting immunotherapy from China’s RemeGen. Elsewhere, Alnylam missed an earnings ...
Pharmaceutical Technology on MSN
JPM26: AbbVie and RemeGen kick off deals with $5.6bn oncology agreement
AbbVie and RemeGen are the first companies to announce a deal at the J.P Morgan Healthcare Conference 2026, with more deals ...
The dual inhibition of PD-1 and VEGF pathways by ivonescimab aims to enhance immune response and limit tumor angiogenesis, ...
The study found significant intra-group CMT reductions in the DEX-I group, with a higher percentage reduction than the ...
Instil's licensed PD-L1xVEGF bispecific shows promise in China, instilling hope for upcoming US test
A PD-L1xVEGF bispecific antibody from China’s ImmuneOnco Biopharmaceuticals has shown early promise in shrinking lung tumors, instilling hope that the asset can succeed in a newly approved U.S. trial.
A single intravitreal injection of UBX1325 (foselutoclax) was shown to be safe in patients with diabetic macular edema. The drug also showed potential efficacy in patients who failed to optimally ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback